BIXTBioxytran, Inc.

About Bioxytran, Inc. (BIXT)

Bioxytran, Inc. (BIXT) is a Biotechnology company headquartered in Needham, MA, United States whose shares trade over-the-counter on the OTCQB tier.

Bioxytran, Inc. is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues. Hypoxia, needs to be addressed quickly, otherwise it results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an Acellular Oxygen Carrier ("AOC") consisting of bovine hemoglobin stabilized with a co-polymer with an intended application that includes the treatment of hypoxic conditions in the brain resulting from stroke. Our subsidiary, Pharmalectin Inc. is focused on the development, manufacturing and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin has developed a novel method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Our lead drug candidate, named ProLectin-M, is a complex polysaccharide derived from natural sources that binds to, and blocks the activity of galectins.

Products and services

Bioxytran’s lead drug candidate, code named BXT-25, an Acellular Oxygen Carrier (“AOC”) consisting of bovine hemoglobin stabilized with a co-polymer is currently proceeding with pre-clinical toxicity studies in animals. Our Subsidiary, Pharmalectin, Inc. (the “Subsidiary”) is focused in the field of glycovirology. The lead drug candidate, code named ProLectin, a complex polysaccharide derived from natural sources that binds to, and blocks the activity of galectins, is currently proceeding with several clinical trials; • a chewable tablet, ProLectin-M, aimed for treatment of mild to moderate cases of Covid-19, and • an IV therapeutic, ProLectin-I, aimed for treatment of Long Covid, as well as • a treatment, ProLectin-F, aimed for idiopathic pulmonary fibrosis (IPF) while currently also investigating other upper-respiratory tract viruses, e.g. RSV and influenza.

BIXT key facts

Ticker symbol

BIXT

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Needham, MA, United States

Country of incorporation

US

Year of incorporation

2008

Employees

6

Estimated market cap

$15.85M (as of Apr 9, 2025)

Shares outstanding

88,881,858

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Bioxytran, Inc. leadership

• David Platt — CEO
• Ola Soderquist — CFO, Secretary, Treasurer
• Mike Sheikh — CCO

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with B